Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Essen Biotech
University of California, Davis
AgonOx, Inc.
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Hadassah Medical Organization
Vastra Gotaland Region
Vastra Gotaland Region
H. Lee Moffitt Cancer Center and Research Institute
Medicenna Therapeutics, Inc.
University of California, San Diego
Case Comprehensive Cancer Center
BioNTech SE
Providence Health & Services
The Netherlands Cancer Institute
Centre Hospitalier Universitaire Vaudois
University of California, San Diego
Vall d'Hebron Institute of Oncology
Hoosier Cancer Research Network
University Hospital, Basel, Switzerland
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Kansas Medical Center
Masonic Cancer Center, University of Minnesota
Clinigen, Inc.
Erasmus Medical Center
Rutgers, The State University of New Jersey
Vastra Gotaland Region
Fate Therapeutics
The Christie NHS Foundation Trust
BGI, China
Sheba Medical Center
Fred Hutchinson Cancer Center
Karolinska University Hospital
PACT Pharma, Inc.
Genocea Biosciences, Inc.
Nantes University Hospital
M.D. Anderson Cancer Center
University Health Network, Toronto
Loma Linda University
Herlev Hospital
M.D. Anderson Cancer Center
Herlev Hospital